Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb extension persistence study of two Haemophilus influenzae type b conjugate vaccines in Chinese children
2015-001453-32Phase 3
- Sponsor
- Novartis
- Start
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Haemophilus b conjugate vaccine in Haemophilus influenzae type b disease (Hib), meningitis, epiglottitis and 2 more (2 arms), sponsored by Novartis. Primary endpoint: Primary immunogenicity endpoint.
02
Drugs
Haemophilus b conjugate vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)meningitisepiglottitispneumoniainfectious arthritis (SA)
Beyond the preview
Go deeper on 2015-001453-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001453-32.